At the news
? MIXEDIMPACT 5/10 8-K filed May 7, 2026 at 08:36 ET
Theravance Biopharma reported Q1 2026 revenue of $17.7M (+15% YoY), slightly above the $17.4M consensus, but GAAP EPS of -$0.10 missed the Street estimate of -$0.05. Net loss improved to -$4.9M from -$13.6M a year ago, and non-GAAP net income turned positive at $0.6M. The company reaffirmed its restructuring and cost-cutting targets, while the strategic review for a potential sale continues.
- Total revenue $17.7M, up 15% YoY from $15.4M, entirely from Viatris collaboration
- GAAP net loss per share -$0.10 vs. consensus -$0.05 (100% miss)
- Net loss narrowed to $4.9M from $13.6M in Q1 2025
- Non-GAAP net income from operations was $0.6M vs. -$8.6M last year
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access